Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase 3 study of bempegaldesleukin (NKTR-214) plus nivolumab versus nivolumab alone in previously untreated unresectable or metastatic melanoma
MOH_2019-02-17_003699Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Nov 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in melanoma comparing bempegaldesleukin + nivolumab with nivolumab monotherapy (2 arms). Started Nov 2018; status: completed.
02
Drugs
bempegaldesleukinnivolumab
03
Conditions
melanoma
Beyond the preview
Go deeper on MOH_2019-02-17_003699.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-02-17_003699.